|
Gene: INSIG2 |
Gene summary for INSIG2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | INSIG2 | Gene ID | 51141 |
Gene name | insulin induced gene 2 | |
Gene Alias | INSIG-2 | |
Cytomap | 2q14.1-q14.2 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | A0A024RAI2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51141 | INSIG2 | GSM4909296 | Human | Breast | IDC | 6.97e-03 | -1.15e-01 | 0.1524 |
51141 | INSIG2 | GSM4909301 | Human | Breast | IDC | 7.26e-03 | -1.21e-01 | 0.1577 |
51141 | INSIG2 | GSM4909302 | Human | Breast | IDC | 6.39e-05 | -1.47e-01 | 0.1545 |
51141 | INSIG2 | GSM4909311 | Human | Breast | IDC | 2.13e-09 | -1.07e-01 | 0.1534 |
51141 | INSIG2 | GSM4909319 | Human | Breast | IDC | 1.78e-08 | -1.51e-01 | 0.1563 |
51141 | INSIG2 | GSM4909321 | Human | Breast | IDC | 1.41e-05 | -1.38e-01 | 0.1559 |
51141 | INSIG2 | ctrl6 | Human | Breast | Precancer | 3.36e-08 | 5.47e-01 | -0.0061 |
51141 | INSIG2 | brca1 | Human | Breast | Precancer | 1.20e-02 | 3.17e-01 | -0.0338 |
51141 | INSIG2 | brca3 | Human | Breast | Precancer | 1.88e-11 | 4.68e-01 | -0.0263 |
51141 | INSIG2 | brca10 | Human | Breast | Precancer | 1.38e-06 | 4.19e-01 | -0.0029 |
51141 | INSIG2 | NCCBC14 | Human | Breast | DCIS | 3.06e-02 | 8.68e-02 | 0.2021 |
51141 | INSIG2 | NCCBC3 | Human | Breast | DCIS | 4.70e-03 | -1.23e-02 | 0.1198 |
51141 | INSIG2 | NCCBC5 | Human | Breast | DCIS | 3.38e-02 | -8.35e-02 | 0.2046 |
51141 | INSIG2 | P1 | Human | Breast | IDC | 8.85e-05 | -8.61e-02 | 0.1527 |
51141 | INSIG2 | DCIS2 | Human | Breast | DCIS | 7.27e-34 | 1.51e-02 | 0.0085 |
51141 | INSIG2 | LZE4T | Human | Esophagus | ESCC | 7.12e-07 | 3.24e-01 | 0.0811 |
51141 | INSIG2 | LZE7T | Human | Esophagus | ESCC | 1.09e-05 | 2.54e-01 | 0.0667 |
51141 | INSIG2 | LZE8T | Human | Esophagus | ESCC | 1.96e-07 | 1.54e-01 | 0.067 |
51141 | INSIG2 | LZE24T | Human | Esophagus | ESCC | 3.39e-15 | 1.86e-01 | 0.0596 |
51141 | INSIG2 | LZE6T | Human | Esophagus | ESCC | 5.56e-03 | 1.73e-01 | 0.0845 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00363141 | Liver | HCC | response to sterol | 24/7958 | 36/18723 | 2.95e-03 | 1.38e-02 | 24 |
GO:00192172 | Liver | HCC | regulation of fatty acid metabolic process | 53/7958 | 93/18723 | 3.36e-03 | 1.53e-02 | 53 |
GO:00192182 | Liver | HCC | regulation of steroid metabolic process | 55/7958 | 100/18723 | 7.79e-03 | 3.09e-02 | 55 |
GO:005123518 | Oral cavity | OSCC | maintenance of location | 182/7305 | 327/18723 | 6.16e-10 | 1.58e-08 | 182 |
GO:003250710 | Oral cavity | OSCC | maintenance of protein location in cell | 49/7305 | 65/18723 | 2.61e-09 | 6.03e-08 | 49 |
GO:004518520 | Oral cavity | OSCC | maintenance of protein location | 65/7305 | 94/18723 | 3.00e-09 | 6.88e-08 | 65 |
GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
GO:00725958 | Oral cavity | OSCC | maintenance of protein localization in organelle | 35/7305 | 42/18723 | 4.58e-09 | 1.01e-07 | 35 |
GO:00069849 | Oral cavity | OSCC | ER-nucleus signaling pathway | 36/7305 | 46/18723 | 6.49e-08 | 1.16e-06 | 36 |
GO:005165120 | Oral cavity | OSCC | maintenance of location in cell | 121/7305 | 214/18723 | 1.39e-07 | 2.32e-06 | 121 |
GO:003286916 | Oral cavity | OSCC | cellular response to insulin stimulus | 114/7305 | 203/18723 | 5.07e-07 | 7.41e-06 | 114 |
GO:00709729 | Oral cavity | OSCC | protein localization to endoplasmic reticulum | 50/7305 | 74/18723 | 6.03e-07 | 8.64e-06 | 50 |
GO:007137510 | Oral cavity | OSCC | cellular response to peptide hormone stimulus | 153/7305 | 290/18723 | 1.23e-06 | 1.63e-05 | 153 |
GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
GO:00060667 | Oral cavity | OSCC | alcohol metabolic process | 179/7305 | 353/18723 | 4.54e-06 | 5.21e-05 | 179 |
GO:003286816 | Oral cavity | OSCC | response to insulin | 138/7305 | 264/18723 | 7.54e-06 | 8.15e-05 | 138 |
GO:00421804 | Oral cavity | OSCC | cellular ketone metabolic process | 111/7305 | 211/18723 | 3.94e-05 | 3.45e-04 | 111 |
GO:00461652 | Oral cavity | OSCC | alcohol biosynthetic process | 77/7305 | 140/18723 | 8.77e-05 | 6.70e-04 | 77 |
GO:00160537 | Oral cavity | OSCC | organic acid biosynthetic process | 155/7305 | 316/18723 | 1.64e-04 | 1.13e-03 | 155 |
GO:00463947 | Oral cavity | OSCC | carboxylic acid biosynthetic process | 154/7305 | 314/18723 | 1.73e-04 | 1.19e-03 | 154 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
INSIG2 | SNV | Missense_Mutation | novel | c.439N>G | p.Thr147Ala | p.T147A | Q9Y5U4 | protein_coding | tolerated(0.54) | probably_damaging(0.983) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
INSIG2 | SNV | Missense_Mutation | rs758358013 | c.382N>A | p.Asp128Asn | p.D128N | Q9Y5U4 | protein_coding | deleterious(0.04) | benign(0.083) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
INSIG2 | SNV | Missense_Mutation | c.565N>T | p.Arg189Cys | p.R189C | Q9Y5U4 | protein_coding | deleterious(0) | benign(0.007) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
INSIG2 | SNV | Missense_Mutation | c.365G>A | p.Ser122Asn | p.S122N | Q9Y5U4 | protein_coding | tolerated(0.07) | benign(0.095) | TCGA-E2-A15J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
INSIG2 | SNV | Missense_Mutation | novel | c.362C>T | p.Ala121Val | p.A121V | Q9Y5U4 | protein_coding | deleterious(0) | benign(0.183) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
INSIG2 | SNV | Missense_Mutation | c.623G>A | p.Arg208Gln | p.R208Q | Q9Y5U4 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
INSIG2 | SNV | Missense_Mutation | novel | c.44G>A | p.Gly15Asp | p.G15D | Q9Y5U4 | protein_coding | deleterious_low_confidence(0.01) | benign(0.133) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
INSIG2 | SNV | Missense_Mutation | rs758358013 | c.382N>A | p.Asp128Asn | p.D128N | Q9Y5U4 | protein_coding | deleterious(0.04) | benign(0.083) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
INSIG2 | SNV | Missense_Mutation | c.565N>T | p.Arg189Cys | p.R189C | Q9Y5U4 | protein_coding | deleterious(0) | benign(0.007) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
INSIG2 | insertion | Frame_Shift_Ins | novel | c.585_586insT | p.Ala198CysfsTer19 | p.A198Cfs*19 | Q9Y5U4 | protein_coding | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
51141 | INSIG2 | NA | antipsychotics | 20877301,18195716,20373477 |
Page: 1 |